[go: up one dir, main page]

PE20090483A1 - Vectores para la expresion multiple de genes - Google Patents

Vectores para la expresion multiple de genes

Info

Publication number
PE20090483A1
PE20090483A1 PE2008000210A PE2008000210A PE20090483A1 PE 20090483 A1 PE20090483 A1 PE 20090483A1 PE 2008000210 A PE2008000210 A PE 2008000210A PE 2008000210 A PE2008000210 A PE 2008000210A PE 20090483 A1 PE20090483 A1 PE 20090483A1
Authority
PE
Peru
Prior art keywords
nucleic acid
polypeptides
acid molecules
homic
nucleic
Prior art date
Application number
PE2008000210A
Other languages
English (en)
Inventor
Nathalie Silvestre
Doris Schmitt
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of PE20090483A1 publication Critical patent/PE20090483A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN VECTOR ADENOVIRAL O POXVIRAL QUE COMPRENDE: i) UNA PRIMERA MOLECULA DE ACIDO NUCLEICO QUE CODIFICA UN PRIMER POLIPEPTIDO; ii) UNA SEGUNDA MOLECULA DE ACIDO NUCLEICO QUE CODIFICA A UN SEGUNDO POLIPEPTIDO TALES COMO POLIPEPTIDOS INMUNOGENICOS O ANTITUMORALES, EN DONDE DICHAS MOLECULAS DE ACIDO NUCLEICO SE OBTIENEN DE SECUENCIAS NATIVAS DE ACIDO NUCLEICO QUE EXHIBEN UN PORCENTAJE DE HOMOLOGIA DE 80% A MAS SOBRE UNA PORCION DE 40 NUCLEOTIDOS CONTINUOS, Y ADEMAS DICHAS MOLECULAS DE ACIDO NUCLEICO SE MODIFICAN PARA REDUCIR EL PORCENTAJE DE HOMOLOGIA A MENOS DE 75%. DICHAS MOLECULAS DE ACIDO NUCLEICO CODIFICAN POLIPEPTIDOS DE PAPILOMAVIRUS TALES COMO E1, E2, E6 Y E7. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL VECTOR O LAS MOLECULAS DE ACIDO NUCLEICO JUNTO CON UN ADYUVANTE QUE ES UN COMPUESTO DE IMIDAZOQUINOLINA
PE2008000210A 2007-05-15 2008-01-29 Vectores para la expresion multiple de genes PE20090483A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07360019 2007-05-15

Publications (1)

Publication Number Publication Date
PE20090483A1 true PE20090483A1 (es) 2009-05-20

Family

ID=39522406

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000210A PE20090483A1 (es) 2007-05-15 2008-01-29 Vectores para la expresion multiple de genes

Country Status (16)

Country Link
US (1) US8337859B2 (es)
EP (1) EP2162544B1 (es)
JP (1) JP5474767B2 (es)
KR (1) KR101514473B1 (es)
CN (1) CN101688223B (es)
AR (1) AR065075A1 (es)
AU (1) AU2008250520B2 (es)
BR (1) BRPI0810305A2 (es)
CA (1) CA2686772C (es)
ES (1) ES2416361T3 (es)
IL (1) IL201963A (es)
MX (1) MX2009012272A (es)
PE (1) PE20090483A1 (es)
RU (1) RU2462513C2 (es)
TW (1) TW200844231A (es)
WO (1) WO2008138648A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008250521B2 (en) 2007-05-15 2013-04-18 Transgene S.A. Signaling peptides
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
MX2012001592A (es) * 2009-08-07 2012-05-22 Transgene Sa Composicion para el tratamiento de la infección del virus de la hepatitis b.
EP2558116B2 (de) * 2010-04-16 2020-01-08 General Vectors GmbH Mittel zur lokalen behandlung von zervixdysplasien
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
US9216213B2 (en) * 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
DK2806889T3 (da) 2012-01-24 2017-11-20 Sanford Health Polynukleotider til behandling af onkogene virale polypeptidpositive tumorer
US10363293B2 (en) * 2013-02-21 2019-07-30 Turnstone Limited Partnership Vaccine composition
SG10201903349YA (en) * 2014-10-14 2019-05-30 Univ Pennsylvania Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
SG11201808809PA (en) * 2016-05-02 2018-11-29 Janssen Vaccine & Prevention B V Therapeutic hpv vaccine combinations
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
EP3461497A1 (en) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
BR112021009929B1 (pt) * 2018-11-21 2023-10-03 Mayo Foundation For Medical Education And Research Adenovírus recombinante, composição farmacêutica compreendendo o mesmo e seus usos para tratamento de câncer
KR20240086779A (ko) * 2022-12-05 2024-06-19 경상국립대학교산학협력단 다중 단백질의 발현을 위한 신규 핵산 구조체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
EP0997462B1 (en) 1997-06-30 2004-12-22 Nippon Kayaku Kabushiki Kaisha Novel naphthyridine derivatives or salts thereof
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
ES2233437T3 (es) * 1999-08-25 2005-06-16 MERCK & CO., INC. Genes sinteticos del papilomavirus optimizados para expresion en celulas humanas.
US7001995B1 (en) 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
WO2003018055A1 (en) * 2001-08-23 2003-03-06 Merck & Co., Inc. Vaccine using papilloma virus e proteins delivered by viral vector
SI1407033T1 (sl) * 2002-05-16 2006-06-30 Bavarian Nordic As Intergenske regije kot insercijska mesta v genomumodificiranega virusavakcinije Ankara (MVA)
BRPI0806350A2 (pt) * 2007-01-30 2011-09-06 Transgene Sa uso de uma molécula de ácido nucléico, uso de um vetor, uso de um particula viral infecciosa, vetores, particula viral infecciosa e composição

Also Published As

Publication number Publication date
RU2462513C2 (ru) 2012-09-27
CA2686772A1 (en) 2008-11-20
ES2416361T3 (es) 2013-07-31
AU2008250520B2 (en) 2013-10-31
IL201963A0 (en) 2011-08-01
AU2008250520A1 (en) 2008-11-20
KR20100019432A (ko) 2010-02-18
MX2009012272A (es) 2009-12-01
JP2010526547A (ja) 2010-08-05
TW200844231A (en) 2008-11-16
US8337859B2 (en) 2012-12-25
RU2009144898A (ru) 2011-06-20
CA2686772C (en) 2015-03-24
HK1135731A1 (en) 2010-06-11
EP2162544A1 (en) 2010-03-17
US20100303838A1 (en) 2010-12-02
KR101514473B1 (ko) 2015-04-22
WO2008138648A1 (en) 2008-11-20
BRPI0810305A2 (pt) 2018-07-10
IL201963A (en) 2013-09-30
AR065075A1 (es) 2009-05-13
CN101688223A (zh) 2010-03-31
JP5474767B2 (ja) 2014-04-16
CN101688223B (zh) 2013-07-31
EP2162544B1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
PE20090483A1 (es) Vectores para la expresion multiple de genes
CL2019002280A1 (es) Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235)
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
WO2008084115A3 (en) Lactococcus promoters and uses thereof
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
MY175477A (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
BR112018069823A2 (pt) molécula de dna, vetor, célula hospedeira, composição, molécula de rna, molécula de ácido nucleico, composição farmacêutica, kit, e, uso de uma utr
BR112012011740A2 (pt) polipeptídeo, composição compreendendo o referido polipeptídeo, complexo de proteína, seqüência de nucleotídeo, vetor de expressão célula, e métodos para a preparação do complexo de proteína, para a preparação de um fviii, e para intensificar uma propriedade farmacocinética no plasma de um fviii
CO7051009A2 (es) Composiciones del factor viii y métodos para hacerlas y usarlas
MX2014007233A (es) Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
MX2011013183A (es) Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
BR112013027305A2 (pt) "polipeptídeo recombinante, composição detergente que o compreende, método para limpeza de produto têxtil, vetor de expressão e célula hospedeira".
AR070491A1 (es) Variante de enzima lipolitica con estabilidad aumentada y polinucleotidos que la codifican
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
GB201201178D0 (en) Novel enzymes
AR071232A1 (es) Proteina hibrida usada como vacuna contra toxinas shiga de e. coli
BR112015000585A2 (pt) cepas mutantes de mycoplasma hyopneumoniae
WO2013060819A3 (en) Transient expression vectors, preparation and uses thereof
ES2676542T3 (es) Composiciones de CDV recombinante y usos de las mismas
RU2015112625A (ru) Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция
IN2014DN09963A (es)
IN2015DN03206A (es)

Legal Events

Date Code Title Description
FD Application declared void or lapsed